TY - JOUR
T1 - Ligand Screening System for the RXRα Heterodimer Using the Fluorescence RXR Agonist CU-6PMN
AU - Kawasaki, Mayu
AU - Motoyama, Tomoharu
AU - Yamada, Shoya
AU - Watanabe, Masaki
AU - Fujihara, Michiko
AU - Kambe, Akira
AU - Nakano, Shogo
AU - Kakuta, Hiroki
AU - Ito, Sohei
N1 - Funding Information:
This work was supported by JSPS KAKENHI Grant Numbers 18K14391 (S.N.), 20J23771 (M.K.), and 21K05395 (S.N.) and by JST, PRESTO Grant Number JPMJPR20AB (S.N.).
Publisher Copyright:
© 2023 American Chemical Society.
PY - 2022
Y1 - 2022
N2 - Retinoid X receptor (RXR), a nuclear receptor (NR) that regulates transcription of target genes in a ligand binding-dependent manner, is of interest as a drug target. RXR agonists have been developed as therapeutic agents for cutaneous invasive T-cell lymphoma (e.g., bexarotene (1)) and investigated as potential anti-inflammatory agents. Screening systems for the binding of RXR alone have been reported. However, although RXRs function as RXR heterodimers, information on systems to evaluate the differential binding of RXR agonists as RXR heterodimers has not been available until recently. Here we show that the fluorescent RXR agonist CU-6PMN (3), designed by our group, can be useful for assessing RXR binding to PPARγ/RXRα, and that the binding data differ from those of RXRα alone. This screening method opens a new avenue for binding assays for RXR heterodimers.
AB - Retinoid X receptor (RXR), a nuclear receptor (NR) that regulates transcription of target genes in a ligand binding-dependent manner, is of interest as a drug target. RXR agonists have been developed as therapeutic agents for cutaneous invasive T-cell lymphoma (e.g., bexarotene (1)) and investigated as potential anti-inflammatory agents. Screening systems for the binding of RXR alone have been reported. However, although RXRs function as RXR heterodimers, information on systems to evaluate the differential binding of RXR agonists as RXR heterodimers has not been available until recently. Here we show that the fluorescent RXR agonist CU-6PMN (3), designed by our group, can be useful for assessing RXR binding to PPARγ/RXRα, and that the binding data differ from those of RXRα alone. This screening method opens a new avenue for binding assays for RXR heterodimers.
KW - Fluorescent agonist
KW - PPAR/RXR heterodimer
KW - Retinoid X receptor
KW - Screening assay
UR - http://www.scopus.com/inward/record.url?scp=85148860810&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85148860810&partnerID=8YFLogxK
U2 - 10.1021/acsmedchemlett.2c00509
DO - 10.1021/acsmedchemlett.2c00509
M3 - Article
AN - SCOPUS:85148860810
SN - 1948-5875
JO - ACS Medicinal Chemistry Letters
JF - ACS Medicinal Chemistry Letters
ER -